1. Intratumoral tertiary lymphoid aggregates observed in PDACs from Panc GVAX–treated patients.
Intratumoral tertiary lymphoid aggregates observed in PDACs from Panc GVAX–treated patients. A, lymphoid aggregates (indicated by arrows) observed in PDACs from Panc GVAX–treated (vaccinated) patients are not seen in Panc GVAX–naïve (unvaccinated) patients. Lymphoid aggregates are composed of T cells (anti-CD3 staining) and B cells (anti-CD20 staining). B, numbers of PDACs with (TLA+) or without (TLA−) at least one lymphoid aggregate present in the intratumoral area in 54 unvaccinated patients and 39 vaccinated patients. Intratumoral lymphoid aggregates are observed specifically in PDACs from vaccinated patients (Fisher exact test, P < 0.001). C, IHC analysis with T-cell markers (CD3, CD4, and CD8), B-cell marker (CD20), and follicular DC marker (CD21). D, IHC analysis of the cell-proliferation marker Ki67. E, IHC analysis of the lymphatic-vessel (arrows) marker D2-40. F, IHC analysis of the chemokine ligand CCL21 (arrows). G, IHC analysis of CD20+ B cells, CD3+ T cells, CD56+ NK cells, and CD1a+ immature DCs. Note that anti-CD56 staining also marks neural tissues. H, IHC analysis of CD68+ and CD163+ macrophages and CD83+ and DC-LAMP+ mature DCs (arrows). All positive IHC signals are in brown.
Eric R. Lutz et al. Cancer Immunol Res 2014;2:
©2014 by American Association for Cancer Research